Reviva Pharmaceuticals Inc Appoints Three New Board Members

SANTA CLARA, Calif.--(BUSINESS WIRE)--Reviva Pharmaceuticals, Inc., (Reviva), a privately held drug discovery and development company, announced today that it has appointed life sciences industry experts, Brian G. Atwood, Sarvajna Dwivedi and Peder K. Jensen to its Board of Directors. "We are extremely pleased to welcome Mr. Atwood, Dr. Jensen and Dr. Dwivedi to the Board," said Laxminarayan Bhat, Founder, President and Chief Executive Officer of Reviva.

Suggested Articles

Myovant’s uterine fibroid drug reduced blood loss in nearly three-quarters of patients, trouncing placebo in the second of two phase 3 studies.

The cystic fibrosis biotech unveiled Belous’ appointment alongside news of the promotion of Geoff Gilmartin to the CMO position.

The series C round is the latest in a series of boosts for Frequency’s attempts to tackle hearing loss through the activation of progenitor cells.